LuciaSeminario VidalMDPhD

Assistant Professor, Co-director of the Cutaneous Lymphoma Clinic, Director of Dermatology Consult Service, Director of Clinical Research

Join to view full profile

Dr. Seminario Vidal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Seminario Vidal's full profile

Already have an account?

Office
13330 Usf Laurel Dr
Tampa, FL 33612
Phone+1 813-974-2201

Fax+1 813-974-4325

Education & Training

University of Alabama Medical CenterResidency, Dermatology, 2013 - 2015
Cayetano Heredia UniversityClass of 2004
University of North CarolinaPhD

Certifications & Licensure

FL State Medical License 2016 - 2026
AL State Medical License 2012 - 2015
American Board of Dermatology Dermatology

Clinical Trials

A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma Start of enrollment: 2013 May 30
Completed
Phase 3
Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma Start of enrollment: 2014 Nov 12
Completed
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) Start of enrollment: 2015 Dec 01
Completed
Phase 3
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL Start of enrollment: 2017 Jan 01
Terminated
Phase 3
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis Start of enrollment: 2017 Mar 28
Completed
Phase 3
Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis Start of enrollment: 2018 Jun 25
Completed
Phase 3
A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Nov 14
Terminated
Phase 2
Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 May 31
Completed
Phase 2
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis Start of enrollment: 2018 Jul 26
Completed
Phase 3
This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). Start of enrollment: 2019 Jan 31
Completed
Phase 3
Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis Start of enrollment: 2019 Jan 31
Completed
Phase 2
A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) Start of enrollment: 2020 Nov 17
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

11 citations
Utility of flow cytometry and gene rearrangement analysis in tissue and blood of patients with suspected cutaneous T‑cell lymphoma
Julie D. Gibbs, Sophia Ma, Anna Kim, Lucia Seminario Vidal, Lubomir Sokol
Oncology Reports. 2020-11-23
33 citations
Pediatric drug reaction with eosinophilia and systemic symptoms: A systematic review of the literature.
Lauren Metterle, Leigh A Hatch, Lucia Seminario-Vidal
Pediatric Dermatology. 2020-01-01
12 citations
Wound care for Stevens-Johnson syndrome and toxic epidermal necrolysis.
Brianna Castillo, Nora Vera, Alex G. Ortega-Loayza, Lucia Seminario-Vidal
Journal of the American Academy of Dermatology. 2018-03-27

Lectures

Pearls for Challenging Cases in Skin of Color
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/2/2019

Other Languages

Spanish